Related Experiment Video
Updated: Oct 12, 2025
Contrast Ultrasound Targeted Treatment of Gliomas in Mice via Drug-Bearing Nanoparticle Delivery and Microvascular Ablation
Published on: December 15, 2010
Thrombolytic Agents: Nanocarriers in Targeted Release
Minghua Shen1, Yujiao Wang2,3, Fan Hu2
1Department of Biochemistry and Molecular Biology, Yanbian University Medical College, Yanji 133002, China.
Insights
Targeted nano-drug delivery systems offer a promising solution to overcome the limitations of current thrombolytic therapies for cardiovascular diseases. This review explores recent advancements in developing these novel systems for effective blood clot treatment.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Cardiovascular Medicine
Background:
- Thrombosis, or blood clots, is a primary cause of cardiovascular diseases, leading to significant morbidity and mortality.
- Existing thrombolytic drugs like urokinase and streptokinase have limitations, including short half-lives, adverse effects, and poor targeting.
Purpose of the Study:
- To review recent advancements in targeted nano-drug delivery systems for thrombosis treatment.
- To highlight how nanotechnology can overcome the shortcomings of conventional thrombolytic agents.
Main Methods:
- Review of current literature on nano-drug delivery systems for thrombolysis.
- Analysis of biological and physical responsive nano-systems.
- Focus on targeted approaches for improved drug delivery.
Main Results:
- Nano-drug delivery systems show potential to enhance thrombolytic therapy efficacy.
- Targeted systems can improve drug concentration at the clot site and reduce systemic side effects.
- Various responsive nano-carriers are being developed for precise thrombus targeting.
Conclusions:
- Targeted nano-drug delivery represents a significant advancement in managing thrombosis.
- Nanotechnology offers a viable strategy to improve the safety and effectiveness of cardiovascular disease treatments.
- Further research into these systems is crucial for clinical translation.
Abstract:
A thrombus, known as a blood clot, may form within the vascular system of the body and impede blood flow. Thrombosis is the most common underlying pathology of cardiovascular diseases, contributing to high morbidity and mortality. However, the main thrombolytic drugs (urokinase, streptokinase, etc.) have shortcomings, including a short half-life, serious side effects and a lack of targeting, that limit their clinical application. The use of nano-drug delivery systems is expected to address these problems and a variety of approaches, including biological and physical responsive systems, have been explored. In this report, recent advances in the development of targeted nano-drug delivery systems are thoroughly reviewed.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins